Peer-reviewed veterinary case report
New antibody fragment shows promise against canine distemper virus
By Li, Yuan et al.·Published in International journal of biological macromolecules·2024·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine distemper virus (CDV)-neutralizing activities of an anti-CDV canine-derived single-chain variable antibody fragment 4-15 (scFv 4-15) screened by phage display technology.
- Species:
- dog
Plain-English summary
A study found that a special antibody fragment called scFv 4-15 can effectively neutralize the canine distemper virus (CDV), which causes severe symptoms like diarrhea, fever, and vomiting in dogs. Currently, there are no effective treatments for dogs infected with CDV, but this new antibody shows promise as a potential therapy. Researchers created this antibody from the blood of a dog that had been vaccinated against CDV and found it could successfully bind to and neutralize the virus in laboratory tests. This could lead to new treatment options for dogs suffering from CDV in the future.
People also search for: dog distemper treatment · canine distemper virus symptoms · scFv antibody for dogs
Abstract
Canine distemper virus (CDV) is a highly contagious pathogen that causes severe diarrhea, fever and vomiting in domestic dogs, posing a serious threat to the dog breeding industry. Currently, there are no effective therapeutic agents for emergency treatment despite the availability of vaccines against CDV infection. Single-chain fragment variable (scFv) antibody has been demonstrated to effectively inhibit virus infections, suggesting a potential candidate as a therapeutic agent for canine distemper. In this study, a phage-displayed scFv library was constructed from the peripheral blood lymphocytes of dog immunized intramuscularly with live-attenuated CDV vaccine, and was subjected to four rounds of pannings against CDV. Subsequent indirect enzyme-linked immunosorbent assay screening revealed high-affinity scFv antibodies specific to CDV, and indirect immunofluorescence assay screening revealed CDV-neutralizing activity of scFv antibodies. Our results showed that a scFv antibody 4-15 (scFv 4-15) with high-affinity binding to CDV and neutralizing activity against CDV was obtained, which displayed effective therapeutic potential in vivo for dogs challenged with a lethal dose of CDV. Conclusively, the scFv 4-15 with high-affinity binding and neutralizing activity to CDV that was obtained by phage display technology provides a promising candidate for the therapeutic agents against CDV infection.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38061526/